PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics ; volume:7 ; number:1 ; day:12 ; month:7 ; year:2017 ; pages:1-11 ; date:12.2017
Scientific reports ; 7, Heft 1 (12.7.2017), 1-11, 12.2017
- Urheber
-
Bychkov, Andrey
- Beteiligte Personen und Organisationen
-
Vutrapongwatana, Usanee
Tepmongkol, Supatporn
Keelawat, Somboon
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-05481-z
- URN
-
urn:nbn:de:101:1-2018080903005639289829
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bychkov, Andrey
- Vutrapongwatana, Usanee
- Tepmongkol, Supatporn
- Keelawat, Somboon
- SpringerLink (Online service)
Ähnliche Objekte (12)
The Role of PSMA PET Imaging in Prostate Cancer Theranostics : A Nationwide Survey
The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey
The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
177Lutetium PSMA-radioligandtherapie bij prostaatkanker
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
The Role of PSMA PET Imaging in Prostate Cancer Theranostics : A Nationwide Survey
The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey
The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
177Lutetium PSMA-radioligandtherapie bij prostaatkanker
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
The Role of PSMA PET Imaging in Prostate Cancer Theranostics : A Nationwide Survey
The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey
The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
177Lutetium PSMA-radioligandtherapie bij prostaatkanker